Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Dow
McKinsey
Harvard Business School
AstraZeneca

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for GTx-024

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug GTx-024?

GTx-024 is an investigational drug.

There have been 30 clinical trials for GTx-024. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2011.

The most common disease conditions in clinical trials are Pancreatic Neoplasms, Prostatic Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are GTx, Columbia University, and Sanofi.

There are forty US patents protecting this investigational drug and five hundred and twenty-three international patents.

Recent Clinical Trials for GTx-024
TitleSponsorPhase
Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary IncontinenceGTxPhase 2
Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary IncontinenceGTxPhase 2
Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast CancerNational Cancer Institute (NCI)Phase 2

See all GTx-024 clinical trials

Clinical Trial Summary for GTx-024

Top disease conditions for GTx-024
Top clinical trial sponsors for GTx-024

See all GTx-024 clinical trials

US Patents for GTx-024

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GTx-024   Start Trial SARMs and method of use thereof University of Tennessee Research Foundation (Knoxville, TN)   Start Trial
GTx-024   Start Trial Selective androgen receptor degrader (SARD) ligands and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) GTX, INC. (Memphis, TN)   Start Trial
GTx-024   Start Trial Selective androgen receptor degrader (SARD) ligands and methods of use thereof GTX, INC. (Memphis, TN)   Start Trial
GTx-024   Start Trial Selective androgen receptor modulator and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Baxter
Harvard Business School
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.